Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

NCT02521792 is registered in ClinicalTrials.gov with Clementia Pharmaceuticals Inc. as lead sponsor.

NCT NCT02521792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02521792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)
Lead sponsor
Clementia Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
December 7, 2015
Completion date
August 4, 2016
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fibrodysplasia ossificans progressiva